In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1041
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients ; day:15 ; month:10 ; year:2021 ; pages:1-13
European journal of clinical pharmacology ; (15.10.2021), 1-13
- Urheber
-
Preijers, T.
Spengler, M. W. F. van
Meijer, K.
Fijnvandraat, K.
Fischer, K.
Leebeek, F. W. G.
Cnossen, M. H.
Mathôt, R. A. A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00228-021-03173-2
- URN
-
urn:nbn:de:101:1-2021122917550443671946
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Preijers, T.
- Spengler, M. W. F. van
- Meijer, K.
- Fijnvandraat, K.
- Fischer, K.
- Leebeek, F. W. G.
- Cnossen, M. H.
- Mathôt, R. A. A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal
The impact of extended half-life versus conventional factor product on hemophilia caregiver burden
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?
Development of a dosing system for individualized therapy with oral films
OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?
Hall of half-life
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal
The impact of extended half-life versus conventional factor product on hemophilia caregiver burden
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?
Development of a dosing system for individualized therapy with oral films
OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?
Hall of half-life
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal
The impact of extended half-life versus conventional factor product on hemophilia caregiver burden
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?
Development of a dosing system for individualized therapy with oral films
OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control
Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?